NanoEntek Sees Increased Demand for 'ADAM-rWBC2' in First Half... Overseas Sales Reach 5.5 Billion KRW

NanoEntek announced on August 6 that overseas sales of its compact blood component analysis system, "ADAM-rWBC," reached approximately 5.5 billion KRW in the first half of the year. This growth is attributed to increased demand for both new installations and replacements of the "ADAM-rWBC2" device, which reduces analysis time and increases the number of tests per hour.

According to the provisional overseas sales figures for "ADAM-rWBC" in the first half of the year, revenue from equipment, consumables, and warranties grew by 32.11%, 6.73%, and 9.91%, respectively, compared to the same period last year. Sales of "ADAM-rWBC2" devices in the United States doubled year-on-year, reaching 88% of last year's total annual equipment sales.

The "ADAM-rWBC2" stands out for reducing the analysis time to 45 seconds, compared to about three minutes for the previous "ADAM-rWBC1," and increasing the number of tests per hour by more than four times. The company explained that this addresses the core needs of blood centers that must conduct a large number of tests within a limited timeframe, leading to expanded demand.

A company representative stated, "The U.S. market has entered a phase of stable growth, driven by increased proactive product replacement demand due to changes in the regulatory and trade environment, such as stricter medical device regulations and tariffs. We are also seeing meaningful results with new sales in European markets, including Germany, so achieving over 10 billion KRW in overseas sales for the 'ADAM-rWBC' series this year should be well within reach."

NanoEntek's "ADAM-rWBC" is an ultra-fast blood component analysis system based on lab-on-a-chip technology, and is the only compact device in the world that automatically counts the number of residual white blood cells in blood bags. After receiving FDA approval in 2012, it was selected as the standard device by the American Red Cross in 2017. It is currently used in over 200 blood centers, including the American Red Cross, private blood centers, and U.S. Army, Navy, and Air Force hospitals. The "ADAM-rWBC2" is a next-generation product that significantly reduces analysis time.

Sales of "ADAM-rWBC" are divided into equipment sales, kit and consumable sales, and warranty sales. Growth in equipment sales leads to increased sales of single-use test kits and warranties, resulting in stable revenue growth and improved profitability. Last year in the United States, sales of consumables and warranties exceeded equipment sales by about 75 times.

NanoEntek is pursuing a strategy to expand warranty sales, taking into account the characteristics of overseas markets that prioritize warranty and customer service. The company conducts preventive maintenance twice a year across the United States to ensure high customer loyalty. U.S. customers are accustomed to a "warranty-centered" culture, where immediate replacement or free repair is expected in case of product issues, which drives demand for NanoEntek's equipment with regular inspection and rapid after-sales service models.

A company representative said, "The ADAM series accounts for 30% of NanoEntek's annual sales and is a key product line. As 'ADAM-rWBC' is used on Air Force One, the aircraft carrying the President of the United States, and at the NATO headquarters in Europe, its unrivaled technological excellence is already recognized globally. We expect to see continued stable growth in the European market following the success in the United States."